The long and winding road to over-the-counter registration

When the TGA initially set the maximum dose for over-the-counter CBD at 60mg, most companies feared it was too low to prove efficacy. Avecho CEO Paul Gavin explains why the biotech firm was “probably the only company in Australia that was disappointed when it went up to 150mg” and outlines the next steps in the race for registration. Steve Jones reports.

Biotech firm Avecho is close to unveiling the next stage of its CBD drug registration pathway with scientists in the final stages of settling on an indication that will underpin its pivotal phase III clinical trials.